These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28540500)

  • 21. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI).
    Rowland M; Cavecchi A; Thielmann F; Kulon J; Shur J; Price R
    Pharm Res; 2018 Nov; 36(1):15. PubMed ID: 30478630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
    Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
    Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J; Chan HK; Gengenbach T; Denman JA
    Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity.
    Elajnaf A; Carter P; Rowley G
    Eur J Pharm Sci; 2006 Dec; 29(5):375-84. PubMed ID: 16952450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor.
    Hoe S; Young PM; Traini D
    J Pharm Sci; 2011 Dec; 100(12):5270-80. PubMed ID: 21850666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. InVitro Evaluation of Optimal Inhalation Flow Patterns for Commercial Dry Powder Inhalers and Pressurized Metered Dose Inhalers With Human Inhalation Flow Pattern Simulator.
    Hira D; Okuda T; Mizutani A; Tomida N; Okamoto H
    J Pharm Sci; 2018 Jun; 107(6):1731-1735. PubMed ID: 29428382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers.
    Shur J; Pitchayajittipong C; Rogueda P; Price R
    Ther Deliv; 2013 Aug; 4(8):925-37. PubMed ID: 23919472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of altitude on inhaler performance.
    Titosky JTF; Morin CMD; Suderman JD; Olfert JS; Finlay WH; Vehring R
    J Pharm Sci; 2014 Jul; 103(7):2116-2124. PubMed ID: 24890630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Explaining electrostatic charging and flow of surface-modified acetaminophen powders as a function of relative humidity through surface energetics.
    Jallo LJ; Dave RN
    J Pharm Sci; 2015 Jul; 104(7):2225-32. PubMed ID: 25974039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation.
    Zhou QT; Morton DA; Yu HH; Jacob J; Wang J; Li J; Chan HK
    J Pharm Sci; 2013 Oct; 102(10):3736-47. PubMed ID: 23904207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions.
    Borgström L; Asking L; Lipniunas P
    J Aerosol Med; 2005; 18(3):304-10. PubMed ID: 16181005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.
    Tavernini S; Farina DJ; Martin AR; Finlay WH
    Pharm Res; 2021 Sep; 38(9):1601-1613. PubMed ID: 34463937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of relative humidity on coating efficiency in nonelectrostatic and electrostatic coating.
    Xu Y; Barringer SA
    J Food Sci; 2008 Aug; 73(6):E297-303. PubMed ID: 19241550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.